Papillomaviruses and HPV vaccination to prevent cervical cancer and other HPV-associated diseases [electronic resource] / Douglas R. Lowy.

By: Lowy, Doug [spk]Material type: FilmFilmSeries: Henry Stewart talksBiomedical & life sciences collection. Viruses and viral diseases : emerging threats to humans and animals: Publisher: London : Henry Stewart Talks, 2007Description: 1 online resource (1 streaming video file (32 min.) : color, sound)Subject(s): Papillomavirus Infections | Papillomavirus Vaccines | Risk Factors | Uterine Cervical Neoplasms -- prevention & control | Virus Diseases | VirusesOnline resources: Click here to access online | Series
Contents:
Contents: Cervical cancer is attributable to multiple HPV types; HPV16 predominates -- Cervical cancer: time line of cervical HPV infections, progression and natural history -- Key features of HPV pathogenesis -- Challenges to development of a preventive HPV vaccine -- A prophylactic vaccine -- Formation of papillomavirus virions -- Two distinct HPV VLP vaccines are under commercial development -- Partial crossprotection against incident infection by other high risk HPV types -- Overall efficacy in preventing HPV cervical disease attributable to incident infection -- HPV life cycle -- How could IM injection of a VLP vaccine prevent mucosal or cutaneous infection at the cervix? -- Outstanding medical issues -- Regulatory status of HPV VLP vaccines -- Pap smear screening without vaccination would prevent more cervical cancer deaths than HPV16/18 vaccination without pap screening -- Limitations of current VLP vaccines.
Tags from this library: No tags from this library for this title. Log in to add tags.
    Average rating: 0.0 (0 votes)
No physical items for this record

Animated audio-visual presentation with synchronized narration.

Title from title frames.

Contents: Cervical cancer is attributable to multiple HPV types; HPV16 predominates -- Cervical cancer: time line of cervical HPV infections, progression and natural history -- Key features of HPV pathogenesis -- Challenges to development of a preventive HPV vaccine -- A prophylactic vaccine -- Formation of papillomavirus virions -- Two distinct HPV VLP vaccines are under commercial development -- Partial crossprotection against incident infection by other high risk HPV types -- Overall efficacy in preventing HPV cervical disease attributable to incident infection -- HPV life cycle -- How could IM injection of a VLP vaccine prevent mucosal or cutaneous infection at the cervix? -- Outstanding medical issues -- Regulatory status of HPV VLP vaccines -- Pap smear screening without vaccination would prevent more cervical cancer deaths than HPV16/18 vaccination without pap screening -- Limitations of current VLP vaccines.

Access restricted to subscribers.

Mode of access: World Wide Web.

Technical University of Mombasa
Tom Mboya Street, Tudor 90420-80100 , Mombasa Kenya
Tel: (254)41-2492222/3 Fax: 2490571